Global Leading Market Research Publisher QYResearch announces the release of its latest report “Pharmaceutical Micro-Pellet Core – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pharmaceutical Micro-Pellet Core market, including market size, share, demand, industry development status, and forecasts for the next few years.
Addressing core industry needs: Many drugs require controlled or extended release to maintain therapeutic levels, reduce dosing frequency, and minimize side effects – but standard tablets release API immediately. Pharmaceutical micro-pellet cores solve this by encapsulating API in small particles (500–1000μm) with enteric or sustained-release coatings for prolonged, targeted delivery. Key drivers include generic extended-release formulations, patient compliance, and bioavailability improvement.
The global market for Pharmaceutical Micro-Pellet Core was estimated to be worth US$ 381 million in 2025 and is projected to reach US$ 573 million, growing at a CAGR of 6.1% from 2026 to 2032. Global production is approximately 49,800 tons, with an average price of US$ 7,150 per ton.
The Pharmaceutical Micro-Pellet Core is a commonly used drug carrier in the pharmaceutical industry, particularly in the formulation of oral medications designed for controlled or extended-release purposes. These micro-pellet cores encapsulate the active pharmaceutical ingredient (API) in small particles, enabling a controlled release of the drug over a prolonged period, which enhances therapeutic efficacy and reduces side effects. The outer layer of the micro-pellet core may consist of a coating that protects the drug from gastric acid and ensures targeted release in the appropriate section of the gastrointestinal tract. Pharmaceutical micro-pellet cores are widely used in the formulation of various drugs such as antibiotics, vitamins, and anticancer agents to improve bioavailability and patient compliance.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098148/pharmaceutical-micro-pellet-core
Market Segmentation & Key Players
The Pharmaceutical Micro-Pellet Core market is segmented as below:
Leading Suppliers: Colorcon, Emilio Castelli, Hanns G Werner, FREUND Corp, MB Sugars and Pharmaceuticals Pvt, Meenaxy Pharma Private Limited, Anhui Sunhere Pharmaceutical Excipients, Asahi Kasei Chemicals, Yuekang Pharmaceutical Group, Zhuhai Rundu Pharmaceutical, Hangzhou Gaocheng Biotech & Health, Jiangsu Dongsheng Pharmaceutical Technology, Hainan Poly Pharm, Zhuhai TOPCHAIN Pharmaceutical.
Segment by Type: Particle Size Below 500 μm | Particle Size 500–1000 μm | Particle Size Above 1000 μm
Segment by Application: Tablet | Capsule
Exclusive Industry Insights
Discrete extrusion-spheronization process: Micro-pellet cores are manufactured via extrusion-spheronization – API + excipients (microcrystalline cellulose, lactose) are wet-massed, extruded, and spheronized into uniform spheres (500–1000μm). Coating (enteric, sustained-release) applied in fluid bed processors.
Technical differentiation – particle size segments:
- Below 500 μm (22% revenue): Fine pellets for multi-particulate capsules, fast disintegration. For pediatric, geriatric formulations.
- 500–1000 μm (58% revenue): Standard range, optimal for coating uniformity. Largest segment, for most controlled-release tablets/capsules.
- Above 1000 μm (20% revenue): Large pellets for once-daily extended release, high drug loading. Fastest-growing (CAGR 6.8%).
Recent 6-month data (Oct 2025 – Mar 2026):
- Tablet application dominates (72% revenue) – compressed into disintegrating or matrix tablets.
- Capsule application fastest-growing (CAGR 6.5%) – multi-particulate capsules with blend of different release profiles.
- Functional coatings (enteric, colon-targeting) applied to 65% of micro-pellet cores.
User case – Generic antibiotic manufacturer (India, 200 tons/year): Developing extended-release micro-pellet core formulation (once-daily vs. immediate-release 4x/day) increased patient compliance by 34% and achieved bioequivalence to branded reference. Product launch generated US$ 45M additional revenue. Micro-pellet core cost: US$ 12/kg; selling price of finished dose: US$ 450/kg.
Application insights: Tablet (72%) – compressed multi-particulate tablets (MUPS), matrix tablets with embedded pellets. Capsule (28%) – multi-particulate capsules (blend of immediate + extended-release pellets), sprinkle capsules for pediatric use.
Critical performance requirements:
- Sphericity: Aspect ratio <1.2 for uniform coating.
- Size uniformity: d50 ±10% of target.
- Friability: <0.5% weight loss.
- Coating adhesion: No cracking during compression (for tablets).
Regional snapshot: North America leads with 42% revenue share (high-value extended-release formulations). Europe holds 28% (established generic ER market). Asia-Pacific fastest-growing (CAGR 7.2%), driven by generic drug manufacturing.
Conclusion
The pharmaceutical micro-pellet core market grows steadily, driven by generic extended-release formulations, patient compliance, and bioavailability improvement. Success depends on sphericity control, coating uniformity, and compression robustness. The projected US$ 573 million market by 2032 appears achievable.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
